Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus

On January 12, Wedbush expert Laura Chico lifted the terms people connected the banal to $95 from $83, citing the company’s caller nationalist offering arsenic the ground for the adjustment. According to a property merchandise aboriginal during the day, the offering generated astir $621 cardinal successful nett proceeds.

Despite the revision, the caller terms people represents a downside of 66% from Tuesday’s adjacent of $280.86. Wedbush maintained an Underperform standing for the shares.

While the steadfast has a bearish outlook for Praxis Precision Medicines, Inc. (NASDAQ:PRAX), Wall Street connected a full remains bullish with a statement Strong Buy standing and a one-year mean stock terms people of $$456.71, representing an upside of 65.63% arsenic of January 12.

In different news, the biopharmaceutical institution connected Monday besides shared its firm outlook for 2026 and mentioned that aggregate readouts were scheduled implicit the adjacent 12-24 months. It is besides readying 2 New Drug Applications (NDA) submissions successful February this twelvemonth to the FDA for Ulixacaltamide successful indispensable tumor and Relutrigine for SCN2A- and SCN8A-DEE.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is simply a biopharmaceutical institution that uses genetics insights to make therapies for cardinal tense strategy disorders.

While we admit the imaginable of PRAX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.